Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas
- PMID: 3319462
- DOI: 10.1007/BF01312469
Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas
Abstract
We report results of a prospective study of daily 5-ASA enema therapy in patients with proctocolitis that was unresponsive to conventional therapy. Forty-seven patients with active colonic inflammation distal to the splenic flexure have been followed for three months to three years. Rapid improvement was noted within three months in 41 of 47 (87%) patients, while six failed therapy. Of the 41 patients responding to therapy, 39 achieved complete remission. Nineteen patients have relapsed at least once following discontinuation of 5-ASA, but 23 of 25 (92%) relapse episodes responded to a course of 5-ASA therapy. Complications of 5-ASA therapy were limited to hemorrhoidal irritation and local perianal injury. We conclude that 5-ASA enema is effective in inducing remission in patients with proctocolitis unresponsive to conventional therapy.
Similar articles
-
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.Gastroenterology. 1987 Jun;92(6):1894-8. doi: 10.1016/0016-5085(87)90621-4. Gastroenterology. 1987. PMID: 3569765 Clinical Trial.
-
Enemas for IBD maintenance therapy.Dig Dis Sci. 1989 May;34(5):803. doi: 10.1007/BF01540359. Dig Dis Sci. 1989. PMID: 2714154 No abstract available.
-
5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results.Am J Gastroenterol. 1987 Aug;82(8):732-7. Am J Gastroenterol. 1987. PMID: 3496786
-
The topical treatment of distal ulcerative colitis.Eur J Gastroenterol Hepatol. 1996 Jun;8(6):599-602. doi: 10.1097/00042737-199606000-00019. Eur J Gastroenterol Hepatol. 1996. PMID: 8823577 Review.
-
Topical salicylate therapy (4-ASA and 5-ASA enemas).Gastroenterol Clin North Am. 1989 Mar;18(1):35-42. Gastroenterol Clin North Am. 1989. PMID: 2563990 Review.
Cited by
-
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis.Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD011450. doi: 10.1002/14651858.CD011450.pub2. Cochrane Database Syst Rev. 2018. PMID: 29338066 Free PMC article.
-
Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.Drugs. 1989 Aug;38(2):267-88. doi: 10.2165/00003495-198938020-00007. Drugs. 1989. PMID: 2670519 Review.
-
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.Drug Saf. 1991 May-Jun;6(3):192-219. doi: 10.2165/00002018-199106030-00005. Drug Saf. 1991. PMID: 1676590 Review.
-
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.Drugs. 1989 Oct;38(4):500-23. doi: 10.2165/00003495-198938040-00003. Drugs. 1989. PMID: 2684592 Review.
-
Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.Gut. 2000 Sep;47(3):410-4. doi: 10.1136/gut.47.3.410. Gut. 2000. PMID: 10940280 Free PMC article.